JARDIANCE® can help protect patients by reducing risk in adult patients with:

T2D + CVD - Reducing the risk of CV death vs placebo in adult patients with T2D and CVD (exploratory endpoint)^1†

HF - Reducing the risk of CV death or hospitalisation for HF vs placebo in adult patients with HF^13,14#

CKD - Reducing risk of CV death or kidney disease progression vs placebo in adult patients with CKD^3*

Cardiovascular death was an exploratory endpoint in the EMPA-REG OUTCOME® study in patients with type 2 diabetes and established cardiovascular disease.

†
EMPA-REG Outcome Trial: A randomised, double-blind, placebo-controlled cardiovascular outcomes trial (n=7020). Patients with T2D and CVD were randomised to receive JARDIANCE® (10mg or 25mg) (n=4687) or placebo (n= 2333) once daily, on top of standard of care. Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke. Primary endpoint for JARDIANCE® (pooled figures for 10mg and 25mg dose vs placebo): 3-point MACE (time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke), 14% RRR (1.6% ARR) HR 0.86, 95% CI 0.74–0.99, p=0.04 for superiority. Pre-defined exploratory endpoint for JARDIANCE® (pooled figures for 10mg and 25mg dose vs placebo): CV death 38% RRR (2.2% ARR) (HR 0.62, 95% CI 0.49–0.77, p<0.001).¹
‡
EMPEROR-Reduced Trial: Phase III randomised, double-blind trial to evaluate efficacy and safety of once-daily JARDIANCE® 10mg (n=1863) compared to placebo (n=1867). Patients were adults with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤40%). JARDIANCE® achieved primary composite endpoint vs placebo: adjudicated CV death or HHF, analysed as time to the first event (RRR-25%, ARR-5.3%).¹³
#
EMPEROR-Preserved Trial: Phase III randomised, double-blind trial to evaluate efficacy and safety of once-daily JARDIANCE® 10mg (n=2997) compared to placebo (n=2991). Patients were adults with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF >40%). JARDIANCE® achieved primary composite endpoint vs placebo: adjudicated CV death or HHF, analysed as time to the first event (RRR-21%, ARR-3.3%).¹⁴
*
EMPA-KIDNEY Trial: The trial enrolled 6,609 patients who had evidence of CKD at risk of kidney disease progression, with and without diabetes, with and without albuminuria. Patients with an eGFR ≥20 to <45 mL/ min/1.73m2, or an eGFR ≥45 to <90 mL/ min/1.73m2 with a UACR ≥200mg/g, were randomised to receive either 10mg empagliflozin (n=3304) or placebo (n=3305) on top of standard of care. JARDIANCE® achieved primary endpoint vs placebo: risk reduction in kidney disease progression or CV death 28% RRR/3.6% ARR (HR=0.72; 95% CI: 0.64, 0.82; p<0.001). Kidney disease progression was defined as end-stage kidney disease (ESKD: the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decrease in the eGFR to <10 mL/min/1.73m2 , a sustained decrease from baseline in the eGFR of at least 40%, or death from renal causes.^3,15

Learn more about JARDIANCE® for:

Explore T2D

Explore CKD

Explore CHF

Knowledge base

Dose & Administration

JARDIANCE® is simple to initiate at 10 mg dosing across all indications.

Safety Profile

Adverse reactions from reported placebo-controlled studies and post-marketing experience.

Events

Explore upcoming stands and symposiums where the JARDIANCE® team will be present

Resources

Helpful resources supporting you every step of the way. 

Abbreviations

ARR: absolute risk reduction; ADA: American Diabetes Association; BP: blood pressure; CAD: coronary artery disease; CHF: chronic heart failure; CKD: chronic kidney failure; CV: cardiovascular; CVD: cardiovascular disease; EASD: European Association for the Study of Diabetes; HF: heart failure; HHF: hospitalization heart failure; LVEF: left ventricular ejection fraction; MACE: major adverse cardiovascular events; MI: myocardial infarction; NYHA: New York Heart Association; NICE: National Institute for Health and Care Excellence; PAD: peripheral artery disease; RRR: relative risk reduction; SGLT2: sodium-glucose co-transporter-2; SGLT2i: sodium- glucose co-transporter-2 inhibitor; T2D: type 2 diabetes mellitus.

Zinman B, et al. N Engl J Med. 2015;373(22):2117–2128.
Haring HU, et al. Diabetes Care. 2014;37:1650–1659.
Herrington WG, et al. N Engl J Med. 2023;388(2):117–127. (EMPA-KIDNEY results and the publication’s Supplementary Appendix.)
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Acad Cardiol. 2022;79(17):e263-e421.
Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, Wada J. Diabetes Obes Metab. 2022;24(12):2283-2296.
de Boer IH, Khunti K, Sadusky T, et al. Diabetes Care. 2022;45(12):3075-3090.
National Institute for Health and Care Excellence (NICE) 2023. Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. Technology Appraisal Guidance TA929. Available from: https://www.nice.org.uk/guidance/ta929.
National Institute for Health and Care Excellence (NICE) 2015. Empagliflozin in combination therapy for treating type 2 diabetes. Technology Appraisal Guidance TA336. Available from: https://www.nice.org.uk/guidance/ta336.
National Institute for Health and Care Excellence (NICE) 2023. Empagliflozin for treating chronic kidney disease. Technology Appraisal Guidance TA942. Available from: https://www.nice.org.uk/guidance/ta942.
National Institute for Health and Care Excellence (NICE) 2022. Empagliflozin for treating chronic heart failure with reduced ejection fraction TA773. Available at: https://www.nice.org.uk/guidance/ta773.
National Institute for Health and Care Excellence (NICE) (2022). Type 2 diabetes in adults: management. NG28. Available at: www.nice.org.uk/guidance/ng28.
JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
Packer M, et al. N Engl J Med. 2020;383(15):1413–1424.
Anker SD, et al. N Engl J Med. 2021;385(16):1451–1461.
JARDIANCE Data on File (EMP 23-22).
Davies MJ et al. Diabetes Care 2022;45(11):2753–2786.
Kidney Disease: Improving Global outcomes (KDIGO) CKD Work Group. Kidney Int. 2024;105(4S):S117-S314.
UKKA treatment of CKD recommendations 2023. Available at: https://guidelines.ukkidney.org/summary-of-recommendations/.
Data on File, EMP 24-03.

PC-GB-110618 | December 2024

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Disclaimer

The content on this website is in relation to adult patients.

Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.

Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.

JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.

Indications

JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

as monotherapy when metformin is considered inappropriate due to intolerance
in addition to other medicinal products for the treatment of diabetes¹

JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.¹

JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.¹

PC-GB-109995 V4 | October 2025

JARDIANCE® can offer
TRIPLE PROTECTION for
eligible patients vs
placebo^1-3

JARDIANCE® can help protect patients by reducing risk in adult patients with:

Click here for a summary of the study designs

AS OF AUGUST 2024